— Elon Musk (@elonmusk) August 22, 2022

Neuralink has not yet begun testing on humans, and the Food and Drug Administration has not indicated how near the firm may be to gaining permission. The majority of co-founders have left the organization since its inception six years ago. Furthermore, a report claims a poor working culture, and the episode may be indicative of Neuralink’s condition as a whole. At least the timing is appropriate. Moreover, the announcement coincides with claims that Neuralink has offered to invest in its rival Synchron, which just completed what is believed to be the first endovascular implantation of a brain-computer interface in the United States. An event like this could clarify questions about Synchron’s possible involvement, although a deal is not guaranteed. Musk founded Neuralink in 2016 with the intention of developing an implantable device that would enable direct human-computer interaction via the brain, as opposed to traditional, slower input technologies such as touch screens, keyboards, and voice assistants. He first proposed the project as a way to help mankind stay up with breakthroughs in artificial intelligence, but more recently, the focus has shifted to developing a gadget to assist disabled individuals in cope up with their disabilities. Check out? Is Elon Musk Starting His Own Social Media Platform?